New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.
J Clin Oncol 2017 Aug 7;35(24):2798-2805. Epub 2017 Jul 7.
Tobias Janowitz, Edward H. Williams, Stephen J. Sammut, Andy G. Lynch, Duncan I. Jodrell, Simon Tavaré, and Helena Earl, Cancer Research UK Cambridge Institute, Tobias Janowitz, Peter B. Thomas, and Duncan I. Jodrell, University of Cambridge, Addenbrooke's Hospital, Cambridge; Andrea Marshall, University of Warwick, Coventry; Nicola Ainsworth, Queen Elizabeth Hospital, King's Lynn; Scott Shepherd, Royal Marsden Hospital, London; Jeff White, NHS Greater Glasgow and Clyde; and Patrick B. Mark, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.

Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App.
EBioMedicine 2017 Mar 2;17:5-6. Epub 2017 Mar 2.
Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, UK; Department of Genito-urinary Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Academic Urology Group, Department of Surgery, University of Cambridge, UK. Electronic address:

Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.
Endocr Relat Cancer 2016 Oct 30;23(10):797-812. Epub 2016 Aug 30.
Uro-Oncology Research GroupCancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK Biomarker InitiativeCancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK Molecular Diagnostics and Therapeutics GroupUniversity College London, London, UK

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
J Natl Cancer Inst 2016 May 11;108(5). Epub 2015 Dec 11.
Affiliations of authors:Cancer Research UK Cambridge Institute, University of Cambridge , Cambridge, UK (MA, CEM, NP, HIZ, AQ, AB, SM, BM, CE, SL, SW, VRZ, GS, RR, HM, AGL, CD, CT, AL, RS, JY, RS, JSC, JRG, ST, DEN); School of Medical Sciences, University of Aberdeen , Aberdeen, UK (FO, IJM); Department of Pathology, Addenbrooke's Hospital , Cambridge, UK (AYW, NS); Institute of Human Genetics, Jena University Hospital , Jena , Germany (ME, KL, WH, AB); Dame Roma Mitchell Cancer Research Laboratories, School of Medicine, Faculty of Health Sciences, University of Adelaide , Australia (LAS, WDT); Freemasons Foundation Centre for Men's Health, School of Medicine, Faculty of Health Sciences, University of Adelaide , Australia (LAS, WDT); Diatherix , Huntsville, AL (EG); Masonic Cancer Center, University of Minnesota , Minneapolis, MN (SMD); The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia , Vancouver BC , Canada (PSR); Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital , Oslo , Norway (IGM); Department of Cancer Prevention, Institute of Cancer Research and Department of Urology, Oslo University Hospital , Oslo , Norway (IGM); Prostate Cancer UK/Movember Centre of Excellence, Queens University , Belfast , UK (IGM); Department of Oncology, Addenbrooke's Hospital , Cambridge, UK (MA, DEN).

HES5 silencing is an early and recurrent change in prostate tumourigenesis.
Endocr Relat Cancer 2015 Apr 5;22(2):131-44. Epub 2015 Jan 5.
Cancer Research UK Cambridge InstituteUniversity of Cambridge, Cambridge, CB2 0RE, UKDivision of Genetics and EpidemiologyThe Institute of Cancer Research, Sutton, UKDepartment of Biological Sciences and School of MedicineUniversity of East Anglia, Norwich, UKRoyal Marsden NHS Foundation TrustLondon and Sutton, UKDepartments of PathologyUrologySurgical OncologyAddenbrooke's Hospital, Hills Road, Cambridge, UK

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
J Pathol 2010 May;221(1):49-56
Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.